Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

PubMed 

Google Scholar 

Ning FL, Lyu J, Pei JP, Gu WJ, Zhang NN, Cao SY, et al. The burden and trend of gastric cancer and possible risk factors in five Asian countries from 1990 to 2019. Sci Rep. 2022;12:5980.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Liu ZH, Zhu BW, Shi M, Qu YR, He XJ, Yuan HL, et al. Profiling of gene fusion involving targetable genes in Chinese gastric cancer. World J Gastrointest Oncol. 2022;14:1528–39.

Article 
PubMed 
PubMed Central 

Google Scholar 

Huang D, Lu N, Fan Q, Sheng W, Bu H, Jin X, et al. HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study. PLoS One. 2013;8:e80290.

Article 
PubMed 
PubMed Central 

Google Scholar 

Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:167–92.

Article 
CAS 
PubMed 

Google Scholar 

Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol. 2023;41:1470–91.

Article 
CAS 
PubMed 

Google Scholar 

Ajani JA, D’Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21:393–422.

Article 
PubMed 

Google Scholar 

National Health Commission of The People’s Republic of China. National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version). Chin. J. Cancer Res. 2022;34:207–37.

Yuan J, Shen L, Liu TS, Xu HT, Yang JW, Wei J, et al. Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification. Ann Oncol. 2023;34:S859–S860.

Article 

Google Scholar 

Gordon A, Johnston E, Lau DK, Starling N. Targeting FGFR2 positive gastroesophageal cancer: current and clinical developments. Onco Targets Ther. 2022;15:1183–96.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X, et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer. 2014;110:967–75.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Liu Q, Huang J, Yan W, Liu Z, Liu S, Fang W. FGFR families: biological functions and therapeutic interventions in tumors. MedComm. 2023;4:e367.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Pant S, Schuler M, Iyer G, et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 2023;24:925–35.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Siefker-Radtke AO, Matsubara N, Park SH, et al. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann Oncol. 2024;35:107–17.

Article 
CAS 
PubMed 

Google Scholar 

Malchers F, Ercanoglu M, Schütte D, Castiglione R, Tischler V, Michels S, et al. Mechanisms of primary drug resistance in FGFR1-amplified lung cancer. Clin Cancer Res. 2017;23:5527–36.

Article 
CAS 
PubMed 

Google Scholar 

Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22:259–67.

Article 
CAS 
PubMed 

Google Scholar 

Smyth EC, Turner N, Pearson A, Peckitt C, Chau I, Watkins D, et al. Phase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results. J Clin Oncol. 2016;34:154.

Van Cutsem E, Bang YJ, Mansoor W, Petty RD, Chao Y, Cunningham D, et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017;28:1316–24.

Article 
PubMed 

Google Scholar 

Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022;23:1430–40.

Article 
CAS 
PubMed 

Google Scholar 

Amgen. Amgen reports fourth quarter and full year 2025 financial results. 2025. https://www.amgen.com/newsroom/press-releases/2026/02/amgen-reports-fourth-quarter-and-full-year-2025-financial-results?_gl=1*1uwsfvd*_up*MQ..*_ga*Mjg2Mzg2NjkyLjE3NzU4NzY2MjI.*_ga_CBMSV0J9VL*czE3NzU4NzY2MjIkbzEkZzEkdDE3NzU4NzY2NDYkajM2JGwwJGgw. Accessed April 11, 2026.